Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-23T03:14:00.609Z Has data issue: false hasContentIssue false
  • English
  • Français

Fluoxetine-induced tardive dyskinesia in a patient with Parkinson's disease

Published online by Cambridge University Press:  24 June 2014

Deshandra M. Raidoo
Deshandra M. Raidoo*
Affiliation:
Sioux Falls Veterans Affairs Health Care System, Sioux Falls, South Dakota, USA Department of Psychiatry, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota, USA
*
Professor Deshandra M. Raidoo, Sioux Falls Veterans Affairs Health Care System, 2501 W 22nd Street, Sioux Falls, South Dakota 57117, USA. Tel: +6053363230; Fax: +6053335387; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Extract

Background: This is a report of a 66-year-old male with Parkinson's disease (PD), depression and anxiety who developed tardive dyskinesia (TD) while on fluoxetine.

Methods: The patient underwent psychiatric, neurological and neuroimaging examination.

Results: The patient's neuroimaging examination was normal, his psychiatric assessment revealed depression and anxiety, and his neurological evaluation diagnosed only mild PD. The patient's TD resolved when fluoxetine was discontinued and recurred upon re-exposure.

Conclusion: This case shows that fluoxetine as monotherapy can be associated with TD especially in patients with concomitant PD. Clinicians must be aware of this side-effect and monitor for features of TD due to antidepressants that are often used to treat comorbid depression in patients with PD.

Keywords

EPSfluoxetineParkinson's diseasetardive dyskinesias
Type
Case Reports
Information
Acta Neuropsychiatrica , Volume 24 , Issue 5 , October 2012 , pp. 306 - 309
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Schillevoort, I, van Puijenbroek, EP, de Boer, A, Roos, RA, Jansen, PA, Leufkens, HG.Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol 2002;17:75–79.CrossRefGoogle ScholarPubMed
2.American Psychiatric Association. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: Task Force on Tardive Dyskinesia, American Psychiatric Association, 1992.Google Scholar
3.Naranjo, CA, Busto, U, Sellers, EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.CrossRefGoogle ScholarPubMed
4.Gerber, PE, Lynd, LD.Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998;32:692–698.CrossRefGoogle ScholarPubMed
5.Gill, HS, DeVane, CL, Risch, SC.Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. Clin Psychopharmacol 1997;17:377–389.CrossRefGoogle ScholarPubMed
6.Leo, RJ.Movementdisorders associated with serotonin selective reuptake inhibitors. J Clin Psychiatry 1996;57:449–454.CrossRefGoogle Scholar
7.Coulter, DM, Pillans, PI.Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995;152:122–125.Google ScholarPubMed
8.Sandler, NH.Tardive dyskinesia associated with fluoxetine. J Clin Psychiatry 1996;57:2.Google ScholarPubMed
9.Fishbain, DA, Dominguez, M, Goldberg, M.Dyskinesia associated with fluoxetine use. Neuropsychiatry Neuropsychol Behav Neurol 1992;5:97–100.Google Scholar
10.Jansen Steur, ENH.Increase in Parkinson disability after fluoxetine medication. Neurology 1993;43:211–213.CrossRefGoogle Scholar
11.Simons, JA.Fluoxetine in Parkinson's disease. Mov Disord 1996;11:581–582.CrossRefGoogle ScholarPubMed
12.Hoerger, M.The primacy of neuroleptic-induced D2 receptor hypersensitivity in tardive dyskinesia. Psychiatry Online 2007;13:18–26.Google Scholar
13.Rizos, E, Douzenis, A, Michopoulos, I, et al. Sertindole in the treatment of tardive dyskinesia in a patient with genetically abnormal dopamine D3 receptors. Acta Neuropsychiatr 2010;22:209–210.CrossRefGoogle Scholar
14.Kapur, S, Remington, G.Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466–476.Google ScholarPubMed
15.Prashanth, LK, Fox, S, Meissner, WG.l-dopa-induced dyskinesia – clinical presentation, genetics and treatment. Int Rev Neurobiol 2011;98:31–54.CrossRefGoogle ScholarPubMed
16.Balsara, JJ, Jadhav, SA, Gaonkar, RK, et al. Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behavior in rats. Psychopharmacology 2005;179:597–605.CrossRefGoogle ScholarPubMed
17.Mcneill, A.Chorea induced by low-dose trazodone. Eur Neurol 2006;55:101–102.CrossRefGoogle ScholarPubMed
18.Leo, RJ.Movement disturbances associated with the use of selective serotonin-reuptake inhibitors. Ann Pharmacother 1998;32:712–714.CrossRefGoogle ScholarPubMed
19.Christodoulou, C, Papadopoulou, A, Rizos, E, et al. Extrapyramidal side effects and suicidal ideation under fluoxetine treatment: a case report. Ann Gen Hosp Psychiatry 2010;9:5.CrossRefGoogle ScholarPubMed
20.Hamilton, MS, Opler, LA.Akathisia, suicidality, and fluoxetine. J Clin Psychiatry 1992;53:401–406.Google ScholarPubMed
21.Wirshing, WC, Van Putten, T, Rosenberg, J, Marder, S, Ahmes, D, Hicks-Gray, T.Fluoxetine, akathisia, and suicidality: is there a causal connection? Arch Gen Psychiatry 1992;49:580–581.Google Scholar
22.Sekine, Y, Suzuki, K, Ramachandran, PV, Backburn, TP, Ashby, CR.Acute and repeated administration of fluoxetine, citalopram and paroxetine significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse 2007;61:72–77.CrossRefGoogle ScholarPubMed